Exploration of pathophysiological pathways for incident atrial fibrillation using a multiplex proteomic chip.


Journal

Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219

Informations de publication

Date de publication:
2020
Historique:
received: 15 10 2019
revised: 27 11 2019
accepted: 23 12 2019
entrez: 24 3 2020
pubmed: 24 3 2020
medline: 24 3 2020
Statut: epublish

Résumé

Atrial fibrillation (AF) is the most common arrhythmia and associated with increased morbidity and mortality. Its increasing prevalence calls for novel biomarkers to identify underlying pathophysiological mechanisms as well as patients at risk. Plasma samples from 1694 individuals from the Swedish population-based Malmö Preventive Project (mean age 69.5 years; 29.3% female; mean follow-up time 9.7±3.1 years) were analysed with the Olink proximity extension assay CVD III panel consisting of 92 proteins to identify proteins associated with incident AF or atrial flutter, referred to as incident AF. Incident cases of AF (n=278) were retrieved by linkage to the registers. Participants were followed until the first episode of AF or until censoring by death or emigration. Bonferroni-corrected multivariable Cox regression models adjusted for known risk factors were used to explore possible associations of the 92 proteins and incidence of AF. Multivariable Cox regression analyses of 11 proteins associated with incident AF (mean follow-up time 9.7±3.1 years) after Bonferroni correction confirmed N-terminal pro-B-type natriuretic peptide (HR per 1 SD increment (95% CI) 1.80 (1.58 to 2.04); p=1.2×10 In a general Swedish population, we confirmed the well-known association of NT-proBNP with incident AF and also identified matrix metalloproteinase-2 and osteopontin as novel risk markers for incident AF, independently of traditional risk factors and NT-proBNP.

Identifiants

pubmed: 32201587
doi: 10.1136/openhrt-2019-001190
pii: openhrt-2019-001190
pmc: PMC7076265
doi:

Substances chimiques

Biomarkers 0
Peptide Fragments 0
SPP1 protein, human 0
pro-brain natriuretic peptide (1-76) 0
Osteopontin 106441-73-0
Natriuretic Peptide, Brain 114471-18-0
MMP2 protein, human EC 3.4.24.24
Matrix Metalloproteinase 2 EC 3.4.24.24

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

e001190

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Europace. 2009 Mar;11(3):332-7
pubmed: 19147485
Pacing Clin Electrophysiol. 2003 Jul;26(7 Pt 2):1583-96
pubmed: 12914607
Circulation. 2010 Jan 19;121(2):200-7
pubmed: 20048208
Cardiology. 2013;126(1):62-8
pubmed: 23867576
Heart. 2013 Dec;99(24):1832-6
pubmed: 24131775
Am Heart J. 2014 Jan;167(1):109-115.e2
pubmed: 24332149
Circulation. 2004 Jan 27;109(3):363-8
pubmed: 14732752
Eur Heart J. 2006 Apr;27(7):802-7
pubmed: 16421174
Arterioscler Thromb Vasc Biol. 2001 Apr;21(4):542-7
pubmed: 11304470
Circulation. 1997 Oct 7;96(7):2455-61
pubmed: 9337224
Physiol Rev. 2007 Oct;87(4):1285-342
pubmed: 17928585
J Cardiovasc Electrophysiol. 2011 Sep;22(9):987-93
pubmed: 21489023
Am Heart J. 2010 Mar;159(3):414-420.e4
pubmed: 20211303
Sci Rep. 2019 Jan 22;9(1):272
pubmed: 30670722
PLoS One. 2014 Apr 22;9(4):e95192
pubmed: 24755770
Circulation. 2009 Nov 3;120(18):1768-74
pubmed: 19841297
J Am Coll Cardiol. 2010 Nov 16;56(21):1712-9
pubmed: 21070922
Circulation. 2001 Dec 11;104(24):2886-91
pubmed: 11739301
Circulation. 2002 Jul 23;106(4):484-90
pubmed: 12135950
J Am Heart Assoc. 2013 Mar 18;2(2):e000102
pubmed: 23537808
Eur J Epidemiol. 2010 Feb;25(2):95-102
pubmed: 19936945
Circulation. 2014 Feb 25;129(8):837-47
pubmed: 24345399
N Engl J Med. 2004 Feb 12;350(7):655-63
pubmed: 14960742
Int J Cardiol. 2016 Nov 15;223:74-81
pubmed: 27541645
Clin Biochem. 2014 Jul;47(10-11):869-75
pubmed: 24201066
J Clin Invest. 2001 May;107(9):1055-61
pubmed: 11342566
Heart. 2017 Mar;103(5):377-382
pubmed: 27609943
Cardiology. 2014;127(1):53-4
pubmed: 24247557
Turk Kardiyol Dern Ars. 2017 Jan;45(1):26-32
pubmed: 28106017
Eur Heart J. 2006 Apr;27(7):766-7
pubmed: 16434412

Auteurs

John Molvin (J)

Department of Clinical Sciences, Lund University, Clinical Research Center, Malmö, Sweden.
Department of Cardiology, Skånes universitetssjukhus Malmö, Malmö, Sweden.

Amra Jujic (A)

Department of Clinical Sciences, Lund University, Clinical Research Center, Malmö, Sweden.
Department of Cardiology, Skånes universitetssjukhus Malmö, Malmö, Sweden.

Olle Melander (O)

Department of Clinical Sciences, Lund University, Clinical Research Center, Malmö, Sweden.
Department of Internal Medicine, Skåne University Hospital, Malmö, Sweden.

Manan Pareek (M)

Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Cardiology, North Zealand Hospital, Hilleröd, Denmark.

Lennart Råstam (L)

Department of Clinical Sciences, Lund University, Clinical Research Center, Malmö, Sweden.

Ulf Lindblad (U)

Department of Public Health and Community Medicine, Sahlgrenska Academy, Goteborg, Sweden.

Bledar Daka (B)

Department of Public Health and Community Medicine, Sahlgrenska Academy, Goteborg, Sweden.

Margret Leosdottir (M)

Department of Clinical Sciences, Lund University, Clinical Research Center, Malmö, Sweden.
Department of Cardiology, Skånes universitetssjukhus Malmö, Malmö, Sweden.

Peter Nilsson (P)

Department of Clinical Sciences, Lund University, Clinical Research Center, Malmö, Sweden.
Department of Internal Medicine, Skåne University Hospital, Malmö, Sweden.

Michael Olsen (M)

Centre for Individualized Medicine in Arterial Diseases, University of Southern Denmark, Odense, Denmark.

Martin Magnusson (M)

Department of Clinical Sciences, Lund University, Clinical Research Center, Malmö, Sweden.
Department of Cardiology, Skånes universitetssjukhus Malmö, Malmö, Sweden.
Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH